EDWARDS LIFESCIENCES ANNOUNCES $750 MILLION ACCELERATED SHARE REPURCHASE
11/01/2022 - 09:00 AM
IRVINE, Calif. Nov. 1, 2022 $750 million of Edwards' common stock. With this transaction, Edwards has repurchased more than $1.7 billion
Under the terms of this ASR, Edwards will receive an initial delivery of approximately 8 million shares and the remainder at the maturity of the ASR. The final number of shares to be repurchased will be based on the volume weighted average share price during the term of the agreement. The company is funding the share repurchase under the ASR with its existing cash.
Following this repurchase, Edwards has approximately $900 million remaining in its share repurchase authorization approved by its Board of Directors.
About Edwards Lifesciences
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape. For more information, visit Edwards.com and follow us on Facebook, Instagram, LinkedIn, Twitter and YouTube.
https://www.prnewswire.com/news-releases/edwards-lifesciences-announces-750-million-accelerated-share-repurchase-301664547.html
SOURCE Edwards Lifesciences Corporation
Edwards Lifesciences Corp
NYSE:EW
EW Rankings
#3019 Ranked by Stock Gains
EW Stock Data
Industry
Surgical Appliance and Supplies Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Irvine
About EW
edwards lifesciences (nyse: ew) is the global leader in the science of heart valves and hemodynamic monitoring. driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that save and enhance lives. headquartered in irvine, california, edwards lifesciences has extensive operations in north america, europe, japan, latin america and asia and currently employs about 6,400 individuals worldwide. for us, helping patients is not a slogan – it's our life’s work. from developing devices that replace or repair a diseased heart valve to creating new technologies that monitor vital signs in the critical care setting, we help ensure that patients regain and even improve their quality of life.
